Benjamin Krantz MD, MBA became President and CEO of Advanced Proteome Therapeutics in July 2021 following two and a half years on the Board of Directors. He is a medical oncologist and was Chief Fellow in hematology/oncology at New York University Langone Medical Center. His research has focused on biomarker and therapeutic development in pancreas ductal adenocarcinoma and has resulted in peer-reviewed articles on novel therapeutics for pancreas cancer and emerging biomarkers for therapeutic selection. He has also been the architect of investigational protocols for the development of new pancreas cancer biomarkers and an early phase therapeutic candidate. He received a Bachelor of Arts from the University of Pennsylvania and received his Doctor of Medicine and Master of Business Administration from Tufts University. He completed his residency in internal medicine at New York-Presbyterian Hospital – Columbia University Medical Center during which time he analyzed investigator intellectual property disclosures as a Columbia Technology Ventures Fellow. He subsequently worked as a hospitalist and clinical/translational researcher at Memorial Sloan Kettering Cancer Center. He maintains an academic affiliation at NYU as a Clinical Assistant Professor in the Division of Hematology and Medical Oncology.